Anodal tDCS
Device2 mA, 10 min, 5 sessions
Other names: neuroConn DCS, model no. 008
NCT Number: NCT03185234
The objective of the clinical trial is to investigate whether weak transcranial direct current stimulation (tDCS) can ameliorate the motor cognitive deficit apraxia during stroke rehabilitation. Stroke patients with apraxia will either receive a real stimulation or a sham stimulation (placebo) for 10 minutes at a time on 5 consecutive days during their in-patient stay in a rehabilitation center. Additionally, motor tasks are performed before and after the stimulation. The effect of the weak current stimulation on motor function is assessed 3-4 days after the last stimulation and 3 months after enrollment.
Looking for future studies?
Notify Me18 year–90 year
All sexes
Interventional
Not applicable
Rehabilitationszentrum Godeshöhe e.V., Bonn, North Rhine-Westphalia, Germany
Despite the high incidence of the motor cognitive deficit apraxia after left-hemispheric stroke, evidence-based therapies do not exist. This randomized controlled clinical trial (RCT) investigates whether anodal transcranial direct current stimulation (tDCS) as an add-on therapy during neuro-rehabilitation can ameliorate apraxic deficits in patients with left hemisphere stroke. Therefore, anodal tDCS is applied over the parietal cortex of the left, lesioned hemisphere with an intensity of 2 mA for 10 minutes at a time on 5 consecutive days in combination with motor tasks before and after the stimulation. The effect of the stimulation is compared to a sham stimulation. Moreover, application of a pre-programmed study mode ensures a double-blind study design (patient and investigator). The performance in the apraxia test KAS (Cologne Apraxia Screening) 3-4 days after the last stimulation, compared to baseline, serves as primary endpoint of the study. Secondary endpoints are evaluated using various apraxia tests, motor tests and neuropsychological tests 3-4 days after the last stimulation and 3 months after enrollment.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
2 mA, 10 min, 5 sessions
Other names: neuroConn DCS, model no. 008
sham stimulation, 10 min, 5 sessions
Other names: neuroConn DCS, model no. 008
Time frame: 3-4 days after stimulation
Degree of apraxia
Time frame: 3 months after enrollment
Degree of apraxia
Time frame: 3-4 days after stimulation, and 3 months after enrollment
Degree of apraxia
Time frame: 3-4 days after stimulation, and 3 months after enrollment
Degree of apraxia
Time frame: 3-4 days after stimulation, and 3 months after enrollment
Degree of apraxia
Time frame: 3-4 days after stimulation, and 3 months after enrollment
Motor function
Time frame: 3-4 days after stimulation, and 3 months after enrollment
Motor function
Time frame: 3-4 days after stimulation, and 3 months after enrollment
Motor function
Time frame: 3-4 days after stimulation, and 3 months after enrollment
Motor function
Time frame: enrollment
Impairment by stroke
Time frame: 3-4 days after stimulation, and 3 months after enrollment
Impairment by stroke
Time frame: 3-4 days after stimulation, and 3 months after enrollment
Aphasia
University of Cologne
Other
Therapeutischer Einsatz Der Schwachen Gleichstromstimulation (tDCS) Bei Motorisch-kognitiven Defiziten Nach Schlaganfall
Acronym: RAdiCS
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04957225
Aphasia, Apraxia of Speech
Stockholm, Sweden
View Trial DetailsNCT04044911
Apraxias, Brain Diseases
View Trial DetailsNCT01483807
Aphasia, Apraxia of Speech
Salt Lake City, Utah, United States
View Trial DetailsNCT02199093
Apraxia, Ideomotor, Apraxias
Granada, Spain
View Trial Details